Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine - An explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction

Medical Hypotheses

Volumn 63, Issue 4, 2004, Pages 699-708

  McCarty, Mark F ^a,b  

^a Pantox Laboratories   (United States)

^b NutriGuard Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BIOLOGICAL MARKER; DIMETHYLARGININASE; DITHIOTHREITOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; POLICOSANOL;

AGING; ATHEROSCLEROSIS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; ENDOTHELIUM LESION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY FAILURE; LIPID DIET; NONHUMAN; OXIDATIVE STRESS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; RENAL OSTEODYSTROPHY; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR; URINE; VASCULAR ENDOTHELIUM;

EID: 8444238877     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2002.11.008     Document Type: Article

References (144)

1. Leiper J., Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res. 43:1999;542-548
2. Lischwe M.A., Roberts K.D., Yeoman L.C., Busch H. Nucleolar specific acidic phosphoprotein C23 is highly methylated. J. Biol. Chem. 257:1982;14600-14602
3. Vallance P., Leone A., Calver A., Collier J., Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 20(Suppl 12):1992;S60-S62
4. Palmer R.M., Rees D.D., Ashton D.S., Moncada S. sc l-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem. Biophys. Res. Commun. 153:1988;1251-1256
5. Ogawa T., Kimoto M., Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J. Biol. Chem. 264:1989;10205-10209
6. Leiper J.M., Santa M.J., Chubb A., MacAllister R.J., Charles I.G., Whitley G.S., et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem. J. 343(Pt 1):1999;209-214
7. MacAllister R.J., Parry H., Kimoto M., Ogawa T., Russell R.J., Hodson H., et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br. J. Pharmacol. 119:1996;1533-1540
8. Boger R.H., Sydow K., Borlak J., Thum T., Lenzen H., Schubert B., et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ. Res. 87:2000;99-105
9. ′ G- dimethylarginine in rats Arch. Biochem. Biophys. 252:1987;526-537
10. McDermott J.R. Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem. J. 154:1976;179-184
11. ′ G-dimethylarginine from the hydrolysate of proteins of bovine brain Biochim. Biophys. Acta. 230:1971;212-222
12. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 339:1992;572-575
13. Wahbi N., Dalton R.N., Turner C., Denton M., Abbs I., Swaminathan R. Dimethylarginines in chronic renal failure. J. Clin. Pathol. 54:2001;470-473
14. Kielstein J.T., Boger R.H., Bode-Boger S.M., Frolich J.C., Haller H., Ritz E., et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc. Nephrol. 13:2002;170-176
15. Zoccali C., Benedetto F.A., Maas R., Mallamaci F., Tripepi G., Malatino L.S., et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am. Soc. Nephrol. 13:2002;490-496
16. Xiao S., Wagner L., Schmidt R.J., Baylis C. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int. 59:2001;1466-1472
17. Kielstein J.T., Boger R.H., Bode-Boger S.M., Frolich J.C., Haller H., Ritz E., et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc. Nephrol. 13:2002;170-176
18. Rostand S.G., Drueke T.B. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 56:1999;383-392
19. Coen G., Calabria S., Bellinghieri G., Pecchini F., Conte F., Chiappini M.G., et al. Parathyroidectomy in chronic renal failure: short- and long-term results on parathyroid function, blood pressure and anemia. Nephron. 88:2001;149-155
20. Kautzky-Wilier A., Pacini G., Barnas U., Ludvik B., Streli C., Graf H., et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int. 47:1995;200-206
21. Fliser D., Franek E., Fode P., Stefanski A., Schmitt C.P., Lyons M., et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol. Dial Transplant. 12:1997;933-938
22. Gunal A.I., Celiker H., Celebi H., Ustundag B., Gunal S.Y. Intravenous alfacalcidol improves insulin resistance in hemodialysis patients. Clin. Nephrol. 48:1997;109-113
23. Cross J.M., Donald A.E., Kharbanda R., Deanfield J.E., Woolfson R.G., MacAllister R.J. Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int. 60:2001;2318-2323
24. Bode-Boger S.M., Boger R.H., Kienke S., Junker W., Frolich J.C. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem. Biophys. Res. Commun. 219:1996;598-603
25. Boger R.H., Bode-Boger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 98:1998;1842-1847
26. Chan J.R., Boger R.H., Bode-Boger S.M., Tangphao O., Tsao P.S., Blaschke T.F., et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler. Thromb. Vase. Biol. 20:2000;1040-1046
27. Goonasekera C.D., Rees D.D., Woolard P., Frend A., Shah V., Dillon M.J. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J. Hypertens. 15:1997;901-909
28. Surdacki A., Nowicki M., Sandmann J., Tsikas D., Boeger R.H., Bode-Boeger S.M., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J. Cardiovasc. Pharmacol. 33:1999;652-658
29. Ito A., Egashira K., Narishige T., Muramatsu K., Takeshita A. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn. Circ. J. 65:2001;775-778
30. Delles C., Schneider M.P., John S., Gekle M., Schmieder R.E. Angiotensin converting enzyme inhibition and angiotensin II ATI-receptor blockade reduce the levels of asymmetrical N (G), N (G)-dimethylarginine in human essential hypertension. Am. J. Hypertens. 15:2002;590-593
31. Boger R.H., Bode-Boger S.M., Sydow K., Heistad D.D., Lentz S.R. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst (e)inemia or hypercholesterolemia. Arterioscler. Thromb. Vase. Biol. 20:2000;1557-1564
32. Boger R.H., Lentz S.R., Bode-Boger S.M., Knapp H.R., Haynes W.G. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst (e)inaemia in humans. Clin. Sci. (Lond). 100:2001;161-167
33. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S., et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 99:1999;1141-1146
34. Asagami T., Abbasi F., Stuelinger M., Lamendola C., McLaughlin T., Cooke J.P., et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 51:2002;843-846
35. Stuhlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 287:2002;1420-1426
36. Lundman P., Eriksson M.J., Stuhlinger M., Cooke J.P., Hamsten A., Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J. Am. Coll. Cardiol. 38:2001;111-116
37. Usui M., Matsuoka H., Miyazaki H., Ueda S., Okuda S., Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 62:1998;2425-2430
38. Feng Q., Lu X., Fortin A.J., Pettersson A., Hedner T., Kline R.L., et al. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc. Res. 37:1998;667-675
39. Zoccali C., Mallamaci F., Maas R., Benedetto F.A., Tripepi G., Malatino L.S., et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 62:2002;339-345
40. Pettersson A., Hedner T., Milsom I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet. Gynecol. Scand. 77:1998;808-813
41. Xiong Y., Yuan L.W., Deng H.W., Li Y.J., Chen B.M. Elevated serum endogenous inhibitor of nitric oxide synthase and endothelial dysfunction in aged rats. Clin. Exp. Pharmacol. Physiol. 28:2001;842-847
42. Lu R., Hu C.P., Wu X.P., Liao E.Y., Li Y.J. Effect of age on bone mineral density and the serum concentration of endogenous nitric oxide synthase inhibitors in rats. Comp. Med. 52:2002;224-228
43. Plotnick G.D., Corretti M.C., Vogel R.A. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA. 278:1997;1682-1686
44. Ling L., Zhao S.P., Gao M., Zhou Q.C., Li Y.L., Xia B. Vitamin C preserves endothelial function in patients with coronary heart disease after a high-fat meal. Clin. Cardiol. 25:2002;219-224
45. Steinberg H.O., Tarshoby M., Monestel R., Hook G., Cronin J., Johnson A., et al. Elevated circulating free fatty acid levels impair endothelium- dependent vasodilation. J. Clin. Invest. 100:1997;1230-1239
46. Steinberg H.O., Paradisi G., Hook G., Crowder K., Cronin J., Baron A.D. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes. 49:2000;1231-1238
47. Frayn K.N. Non-esterified fatty acid metabolism and postprandial lipaemia. Atherosclerosis. 141(Suppl 1):1998;S41-S46
48. Fard A., Tuck C.H., Donis J.A., Sciacca R., Di Tullio M.R., Wu H.D., et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler. Thromb. Vase. Biol. 20:2000;2039-2044
49. Boger R.H., Bode-Boger S.M. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Semin. Thromb. Hemost. 26:2000;539-545
50. Cooke J.P., Oka R.K. Atherogenesis and the arginine hypothesis. Curr. Atheroscler. Rep. 3:2001;252-259
51. Tsikas D., Boger R.H., Sandmann J., Bode-Boger S.M., Frolich J.C. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett. 478:2000;1-3
52. Arnal J.F., Dinh-Xuan A.T., Pueyo M., Darblade B., Rami J. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell. Mol. Life Sci. 55:1999;1078-1087
53. Collins T. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab. Invest. 68:1993;499-508
54. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., Cooke J.P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 99:1999;3092-3095
55. Leiper J.M., Santa M.J., Chubb A., MacAllister R.J., Charles I.G., Whitley G.S., et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem. J. 343(Pt 1):1999;209-214
56. Wascher T.C., Posch K., Wallner S., Hermetter A., Kostner G.M., Graier W.F. Vascular effects of L-arginine: anything beyond a substrate for the NO- synthase? Biochem. Biophys. Res. Commun. 234:1997;35-38
57. Stuhlinger M.C., Tsao P.S., Her J.H., Kimoto M., Balint R.F., Cooke J.P. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 104:2001;2569-2575
58. Meyer J.W., Holland J.A., Ziegler L.M., Chang M.M., Beebe G., Schmitt M.E. Identification of a functional leukocyte-type NADPH oxidase in human endothelial cells :a potential atherogenic source of reactive oxygen species. Endothelium. 7:1999;11-22
59. Zhang H., Schmeisser A., Garlichs C.D., Plotze K., Damme U., Mugge A., et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc. Res. 44:1999;215-222
60. Harrison D.G. Endothelial function and oxidant stress. Clin. Cardiol. 20(Suppl 2):1997;11-17
61. Holland J.A., O'Donnell R.W., Chang M.M., Johnson D.K., Ziegler L.M. Endothelial cell oxidant production: effect of NADPH oxidase inhibitors. Endothelium. 7:2000;109-119
62. Katusic Z.S. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role. Am. J. Physiol. Heart Circ. Physiol. 281:2001;H981-H986
63. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87:2000;840-844
64. Wolin M.S., Gupte S.A., Oeckler R.A. Superoxide in the vascular system. J. Vascul. Res. 39:2002;191-207
65. Rieger J.M., Shah A.R., Gidday J.M. Ischemia-reperfusion injury of retinal endothelium by cyclooxygenase- and xanthine oxidase-derived superoxide. Exp. Eye. Res. 74:2002;493-501
66. Meneshian A., Bulkley G.B. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation. 9:1902;161-175
67. John S., Schmieder R.E. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J. Hypertens. 18:2000;363-374
68. Zalba G., Beaumont J., San Jose G., Fortuno A., Fortuno M.A., Diez J. Vascular oxidant stress: molecular mechanisms and pathophysiological implications. J. Physiol. Biochem. 56:2000;57-64
69. Perticone F., Ceravolo R., Maio R., Cloro C., Candigliota M., Scozzafava A., et al. Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. Atherosclerosis. 152:2000;511-518
70. Lang D., Kredan M.B., Moat S.J., Hussain S.A., Powell C.A., Bellamy M.F., et al. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arterioscler Thromb. Vase. Biol. 20:2000;422-427
71. McDowell I.F., Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J. Nutr. 130:2000;369S-372S
72. Eberhardt R.T., Forgione M.A., Cap A., Leopold J.A., Rudd M.A., Trolliet M., et al. Endothelial dysfunction in a murine model of mild hyperhomocyst (e)inemia. J. Clin. Invest. 106:2000;483-491
73. Meyer J.W., Schmitt M.E. A central role for the endothelial NADPH oxidase in atherosclerosis. FEBS Lett. 472:2000;1-4
74. Rueckschloss U., Galle J., Holtz J., Zerkowski H.R., Morawietz H. Induction of NAD (P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation. 104:2001;1767-1772
75. Hathaway C.A., Heistad D.D., Piegors D.J., Miller F.J.J. Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ. Res. 90:2002;277-283
76. Inoguchi T., Li P., Umeda F., Yu H.Y., Kakimoto M., Imamura M., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD (P)H oxidase in cultured vascular cells. Diabetes. 49:2000;1939-1945
77. Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 88:2001;E14-E22
78. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280:2001;E685-E694
79. Perticone F., Ceravolo R., Candigliota M., Ventura G., lacopino S., Sinopoli F., et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes. 50:2001;159-165
80. Shinozaki K., Hirayama A., Nishio Y., Yoshida Y., Ohtani T., Okamura T., et al. Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. J. Am. Coll. Cardiol. 38:2001;1821-1828
81. Pleiner J., Schaller G., Mittermayer F., Bayerle-Eder M., Roden M., Wolzt M. FFA-induced endothelial dysfunction can be corrected by vitamin C. J. Clin. Endocrinol. Metab. 87:2002;2913-2917
82. Indik J.H., Goldman S., Gaballa M.A. Oxidative stress contributes to vascular endothelial dysfunction in heart failure. Am. J. Physiol. Heart Circ. Physiol. 281:2001;H1767-H1770
83. Richartz B.M., Werner G.S., Ferrari M., Figulla H.R. Reversibility of coronary endothelial vasomotor dysfunction in idiopathic dilated cardiomyopathy: acute effects of vitamin C. Am. J. Cardiol. 88:2001;1001-1005
84. Sharma R., Davidoff M.N. Oxidative stress and endothelial dysfunction in heart failure. Congest. Heart Fail. 8:2002;165-172
85. Motoyama T., Kawano H., Hirai N., Tsunoda R., Moriyama Y., Miyao Y., et al. The relationship of left ventricular mass to endothelium-dependent vasodilation of the brachial artery in patients with hypertension. Cardiology. 96:1902;7-15
86. Davidge S.T. Oxidative stress and altered endothelial cell function in preeclampsia. Semin. Reprod. Endocrinol. 16:1998;65-73
87. Roggensack A.M., Zhang Y., Davidge S.T. Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension. 33:1999;83-89
88. Hubel C.A. Oxidative stress in the pathogenesis of preeclampsia. Proc. Soc. Exp. Biol. Med. 222:1999;222-235
89. Chambers J.C., Fusi L., Malik I.S., Haskard D.O., De Swiet M., Kooner J.S. Association of maternal endothelial dysfunction with preeclampsia. JAMA. 285:2001;1607-1612
90. van der Loo B., Labugger R., Skepper J.N., Bachschmid M., Kilo J., Powell J.M., et al. Enhanced peroxynitrite formation is associated with vascular aging. J. Exp. Med. 192:2000;1731-1744
91. Csiszar A., Ungvari Z., Edwards J.G., Kaminski P., Wolin M.S., Koller A., et al. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ. Res. 90:2002;1159-1166
92. Bae J.H., Bassenge E., Kim K.B., Kim Y.N., Kim K.S., Lee H.J., et al. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis. 155:2001;517-523
93. Holmgren A. Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure. 3:1995;239-243
94. McCarty M.F. Oxidants downstream from superoxide inhibit nitric oxide production by vascular endothelium - a key role for selenium-dependent enzymes in vascular health. Med. Hypoth. 53:1999;315-325
95. Holben D.H., Smith A.M. The diverse role of selenium within selenoproteins: a review. J. Am. Diet Assoc. 99:1999;836-843
96. Wagner A.H., Kohler T., Ruckschloss U., Just I., Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vase. Biol. 20:2000;61-69
97. Thakur N.K., Hayashi T., Sumi D., Kano H., Tsunekawa T., Iguchi A. HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide. Am. J. Physiol. Heart Circ. Physiol. 281:2001;H75-H83
98. Laufs U., Liao J.K. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc. Med. 10:2000;143-148
99. Endres M., Laufs U. HMG-CoA reductase inhibitor and risk of stroke. Nervenarzt. 69:1998;717-721
100. Gouni-Berthold I., Berthold H.K. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am. Heart J. 143:2002;356-365
101. Menendez R., Amor A.M., Rodeiro I., Gonzalez R.M., Gonzalez P.C., Alfonso J.L., et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch. Med. Res. 32:2001;8-12
102. Boger R.H., Bode-Boger S.M., Mugge A., Kienke S., Brandes R., Dwenger A., et al. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 117:1995;273-284
103. McDonald K.K., Zharikov S., Block E.R., Kilberg M.S. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox" J. Biol. Chem. 272:1997;31213-31216
104. Hardy T.A., May J.M. Coordinate regulation of L-arginine uptake and nitric oxide synthase activity in cultured endothelial cells. Free Radic. Biol. Med. 32:2002;122-131
105. Heller R., Munscher-Paulig F., Grabner R., Till U. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J. Biol. Chem. 274:1999;8254-8260
106. Milstien S., Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem. Biophys. Res. Commun. 263:1999;681-684
107. Huang A., Vita J.A., Venema R.C., Keaney J.F.J. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J. Biol. Chem. 275:2000;17399-17406
108. Cosentino F., Luscher T.F. Tetrahydrobiopterin and endothelial function. Eur. Heart. J. 19(SupplG):1998;G3-G8
109. Vasquez-Vivar J., Martasek P., Whitsett J., Joseph J., Kalyanaraman B. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. Biochem. J. 362:2002;733-739
110. Heitzer T., Krohn K., Albers S., Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia. 43:2000;1435-1438
111. Setoguchi S., Mohri M., Shimokawa H., Takeshita A. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J. Am. Coll. Cardiol. 38:2001;493-498
112. Fukuda Y., Teragawa H., Matsuda K., Yamagata T., Matsuura H., Chayama K. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart. 87:2002;264-269
113. Setoguchi S., Hirooka Y., Eshima K., Shimokawa H., Takeshita A. Tetrahydrobiopterin improves impaired endothelium-dependent forearm vasodilation in patients with heart failure. J. Cardiovasc. Pharmacol. 39:2002;363-368
114. Higashi Y., Sasaki S., Nakagawa K., Fukuda Y., Matsuura H., Oshima T., et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am. J. Hypertens. 15:2002;326-332
115. Fukuda Y., Teragawa H., Matsuda K., Yamagata T., Matsuura H., Chayama K. Tetrahydrobiopterin improves coronary endothelial function, but does not prevent coronary spasm in patients with vasospastic angina. Circ. J. 66:2002;58-62
116. Barchowsky A., Munro S.R., Morana S.J., Vincenti M.P., Treadwell M. Oxidant-sensitive and phosphorylation-dependent activation of NF-kappa B and AP-1 in endothelial cells. Am. J. Physiol. 269:1995;L829-L836
117. Pueyo M.E., Gonzalez W., Nicoletti A., Savoie F., Arnal J.F., Michel J.B. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler. Thromb. Vase. Biol. 20:2000;645-651
118. Ogata N., Yamamoto H., Kugiyama K., Yasue H., Miyamoto E. Involvement of protein kinase C in superoxide anion-induced activation of nuclear factor-kappa B in human endothelial cells. Cardiovasc. Res. 45:2000;513-521
119. Peng H.B., Libby P., Liao J.K. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J. Biol. Chem. 270:1995;14214-14219
120. De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone M.A.J., et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96:1995;60-68
121. Laroux F.S., Lefer D.J., Kawachi S., Scalia R., Cockrell A.S., Gray L., et al. Role of nitric oxide in the regulation of acute and chronic inflammation. Antioxid. Redox. Signal. 2:2000;391-396
122. Spiecker M., Darius H., Kaboth K., Hubner F., Liao J.K. Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J. Leukoc. Biol. 63:1998;732-739
123. Achan V., Iran C.T., Arrigoni F., Whitley G.S., Leiper J.M., Vallance P. All-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ. Res. 90:2002;764-769
124. Bogle R.G., Ccade S.B., Moncada S., Pearson J.D., Mann G.E. Bradykinin and ATP stimulate L-arginine uptake and nitric oxide release in vascular endothelial cells. Biochem. Biophys. Res. Commun. 180:1991;926-932
125. Bogle R.G., Baydoun A.R., Pearson J.D., Mann G.E. Regulation of sc l-arginine transport and nitric oxide release in superfused porcine aortic endothelial cells. J. Physiol. 490(Pt 1):1996;229-241
126. Sobrevia L., Yudilevich D.L., Mann G.E. Activation of A2-purinoceptors by adenosine stimulates L-arginine transport (system y+) and nitric oxide synthesis in human fetal endothelial cells. J. Physiol. 499(Pt 1):1997;135-140
127. Posch K., Schmidt K., Graier W.F. Selective stimulation of L-arginine uptake contributes to shear stress-induced formation of nitric oxide. Life. Sci. 64:1999;663-670
128. Zharikov S.I., Herrera H., Block E.R. Role of membrane potential in hypoxic inhibition of L-arginine uptake by lung endothelial cells. Am. J. Physiol. 272:1997;L78-L84
129. Zharikov S.I., Block E.R. Characterization of L-arginine uptake by plasma membrane vesicles isolated from cultured pulmonary artery endothelial cells. Biochim. Biophys. Acta. 1369:1998;173-183
130. McCabe R.D., Bakarich M.A., Srivastava K., Young D.B. Potassium inhibits free radical formation. Hypertension. 24:1994;77-82
131. McCarty M.F. Endothelial membrane potential regulates production of both nitric oxide and superoxide - fundamental determinant of vascular health. Med. Hypoth. 53:1999;277-289
132. Sohn H.Y., Keller M., Gloe T., Morawietz H., Rueckschloss U., Pohl U. The small G-protein Rac mediates depolarization-induced superoxide formation in human endothelial cells. J. Biol. Chem. 275:2000;18745-18750
133. Yokoyama M., Hirata K., Miyake R., Akita H., Ishikawa Y., Fukuzaki H. Lysophosphatidylcholine: essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low density lipoprotein. Biochem. Biophys. Res. Commun. 168:1990;301-308
134. Murohara T., Kugiyama K., Ohgushi M., Sugiyama S., Ohta Y., Yasue H. LPC in oxidized LDL elicits vasocontraction and inhibits endothelium- dependent relaxation. Am. J. Physiol. 267:1994;H2441-H2449
135. Heinloth A., Heermeier K., Raff U., Wanner C., Galle J. Stimulation of NADPH oxidase by oxidized low-density lipoprotein induces proliferation of human vascular endothelial cells. J. Am. Soc. Nephrol. 11:2000;1819-1825
136. Kikuta K., Sawamura T., Miwa S., Hashimoto N., Masaki T. High-affinity arginine transport of bovine aortic endothelial cells is impaired by lysophosphatidylcholine. Circ. Res. 83:1998;1088-1096
137. Jin L., Abou-Mohamed G., Caldwell R.B., Caldwell R.W. Endothelial cell dysfunction in a model of oxidative stress. Med. Sci. Monit. 7:2001;585-591
138. Xiao S., Wagner L., Mahaney J., Baylis C. Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells. Am. J. Physiol. Renal Physiol. 280:2001;F989-F995
139. Xiao S., Erdely A., Wagner L., Baylis C. Uremic levels of BUN do not cause nitric oxide deficiency in rats with normal renal function. Am. J. Physiol. Renal Physiol. 280:2001;F996-F1000
140. Kaye D.M., Ahlers B.A., Autelitano D.J., Chin-Dusting J.P. In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation. 102:2000;2707-2712
141. Azuma H., Sato J., Hamasaki H., Sugimoto A., Isotani E., Obayashi S. Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br. J. Pharmacol. 115:1995;1001-1004
142. Valkonen V.P., Paiva H., Salonen J.T., Lakka T.A., Lehtimaki T., Laakso J., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 358:2001;2127-2128
143. Zoccali C., Bode-Boger S., Mallamaci F., Benedetto F., Tripepi G., Malatino L., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 358:2001;2113-2117
144. Yoo J.H., Lee S.C. Elevated levels of plasma homocyst (e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis. 158:2001;425-430